Abacavir/Lamivudine/Dolutegravir
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Abacavir/Lamivudine/Dolutegravir, covering 2016-02-22 to 2016-02-22. Get the full timeline:
Most recent: Clinical Trial Update: Multicentric Open-label Study of Switch From Abacavir/Lamivudine Fixed Dose Combination Plus Nevirapine to Abacavir/Lamivudine/Dolutegravir in Virologically Suppressed HIV-1 Infected Adults (SWAD) [Phase 2]